• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome without serious adverse events

byMinjee Kim
February 3, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. There was a dose-related decrease in disease activity from baseline to 24-weeks for patients on ianalumab compared to placebo.

2. There were no serious adverse events from the maximum dose of 300 mg ianalumab, and it was well tolerated by trial participants.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Sjögren’s syndrome is an autoimmune disorder which is currently only treated with symptomatic management of common features, such as dryness, fatigue, and pain. The goal of this phase 2 randomized control trial was to evaluate the safe and effective doses of a new biologic, ianalumab. Patients with primary Sjögren’s syndrome were enrolled and randomized (1:1:1:1) to receive either subcutaneous placebo, 5 mg ianalumab, 50 mg ianalumab, or 300 mg ianalumab over a 24-week period. The primary outcome was a physician-evaluated disease activity index (ESSDAI) score measured every 4 weeks from baseline. Other scores measured included the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and Patient Global Assessment (PaGA). Measurements of salivary and tear production were also measured throughout the study period. This study met its primary outcome of showing a dose-dependent decrease in ESSDAI score during the 24-week treatment period, with the greatest differences seen in the 300 mg ianalumab group. Adverse events on the maximum dose of ianalumab were also found to be minimal, with the main reported adverse being a local site reaction to the injection. Limitations to this study include a large placebo effect seen, which should be considered for future trials. Nonetheless, this study opens the possibility of future trials for the treatment of Sjögren’s syndrome.

Click to read the study in The Lancet.

Relevant Reading: Severe health-related quality of life impairment in active primary Sjögren’s syndrome and patient-reported outcomes: data from a large therapeutic trial.

RELATED REPORTS

Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome

Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome

Patient Basics: Sjögren’s Syndrome

In-Depth [randomized control trial]: Patients aged 18-75 years with primary Sjögren’s were eligible for this double-blind randomized control trial. Participants (n=190) were randomly assigned to receive either placebo (n=49) or 5 mg (n=47), 50 mg (n=47) or 300 mg (n=47) of ianalumab. Most patients were female (95%), and average age was approximately 50 years. The primary outcome was reported as disease activity using the ESSDAI score and the Physician Global Assessment (PhGA). Patient reported severity was collected using the PaGA and the ESSPRI score which measures the symptoms of pain, dryness and fatigue. Secondary outcomes included the objective measurements of tears and salivary flow, as well as other quality of life scales. Assessment was done every 4 weeks from baseline up to 24 weeks.

A dose-dependent decrease in ESSDAI score was seen over the 24-week period. Adjusted for the decrease also seen in the placebo group, the 300 mg ianalumab group saw a -1.92 point (95% CI -4.15 to 0.32, p=0.093) change in least-squares mean ESSDAI score from baseline. No major change was seen in ESSPRI. There was a decrease in PhGA by -8.4 (p=0.022) and PaGA by -4.77 (p=0.32). Tear flow did not change significantly, but stimulated salivary flow improved significantly with a least-squares mean change of 0.20 mL/min (p=0.037) among ianalumab 300 mg versus placebo. There were more incidences of leukopenia in the 300 mg group (13%) compared to 50 mg and placebo (both 4%), but these were not severe grade by CTC criteria. There was no increase in serious adverse events between treatment groups.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ESSPRIianalumabPaGASjogren's treatmentSjögren’s Syndrome
Previous Post

Wellness Check: Addictions

Next Post

Effectiveness of sacubitril-valsartan in post-myocardial infarction management

RelatedReports

Chronic Disease

Low-dose interleukin 2 may be beneficial for primary Sjögren syndrome

December 13, 2022
Autoantibodies may precede symptom onset in Sjögren’s Syndrome
Chronic Disease

Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome

January 26, 2022
Health A to Z

Patient Basics: Sjögren’s Syndrome

November 30, 2014
No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]
Chronic Disease

No benefit with hydroxychloroquine (Plaquenil) over placebo in Sjogren’s Syndrome [JOQUER Trial]

July 15, 2014
Next Post
Patient Basics: Heart Attack (Myocardial Infarction)

Effectiveness of sacubitril-valsartan in post-myocardial infarction management

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial

Psychosocial barriers may hinder expanded buprenorphine access amongst opioid use disorder patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Abnormal menstruation may be associated with worse cardiometabolic outcomes later in life
  • Past infection with pre-omicron variants of COVID-19 protects against re-infection
  • No difference in complete expulsion of intrauterine device between early and standard interval postpartum placement
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options